Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Non-Current Liabilities (2016 - 2025)

Tg Therapeutics has reported Total Non-Current Liabilities over the past 10 years, most recently at $413.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $413.1 million for Q4 2025, up 17.52% from a year ago — trailing twelve months through Dec 2025 was $413.1 million (up 17.52% YoY), and the annual figure for FY2025 was $413.1 million, up 17.52%.
  • Total Non-Current Liabilities for Q4 2025 was $413.1 million at Tg Therapeutics, down from $415.8 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for TGTX hit a ceiling of $424.0 million in Q2 2025 and a floor of $97.5 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $215.5 million (2024), compared with a mean of $256.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 5.19% in 2022 and later soared 108.34% in 2024.
  • Tg Therapeutics' Total Non-Current Liabilities stood at $142.1 million in 2021, then dropped by 5.19% to $134.7 million in 2022, then rose by 25.22% to $168.7 million in 2023, then soared by 108.34% to $351.5 million in 2024, then increased by 17.52% to $413.1 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $413.1 million (Q4 2025), $415.8 million (Q3 2025), and $424.0 million (Q2 2025) per Business Quant data.